|
1
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goral V: Pancreatic cancer: Pathogenesis
and diagnosis. Asian Pac J Cancer Prev. 16:5619–5624. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carrato A, Falcone A, Ducreux M, Valle JW,
Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and
Parthenaki I: A systematic review of the burden of pancreatic
cancer in Europe: Real-world impact on survival, quality of life
and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su D, Yamaguchi K and Tanaka M: The
characteristics of disseminated tumor cells in pancreatic cancer: A
black box needs to be explored. Pancreatology. 5:316–324. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Li Y, Wan L, Chen R and Chen F:
miR-509-5p inhibits cellular proliferation and migration via
targeting MDM2 in pancreatic cancer cells. Onco Targets Ther.
10:4455–4464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shah MY, Ferrajoli A, Sood AK,
Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an
emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re32015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simonson B and Das S: MicroRNA
therapeutics: The next magic bullet? Mini Rev Med Chem. 15:467–474.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shrestha A, Mukhametshina RT, Taghizadeh
S, Vasquez-Pacheco E, Cabrera-Fuentes H, Rizvanov A, Mari B,
Carraro G and Bellusci S: MicroRNA-142 is a multifaceted regulator
in organogenesis, homeostasis, and disease. Dev Dynam. 246:285–290.
2017. View Article : Google Scholar
|
|
16
|
Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng
Y, Guo X, Zhang J, Zhang Q, Zhang L, et al: miR-142-5p regulates
tumor cell PD-L1 expression and enhances anti-tumor immunity.
Biochem Biophys Res Commun. 488:425–431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu L, Liu S, Duan Q, Chen L, Wu T, Qian
H, Yang S, Xin D, He Z and Guo Y: MicroRNA-142-5p promotes cell
growth and migration in renal cell carcinoma by targeting BTG3. Am
J Transl Res. 9:2394–2402. 2017.PubMed/NCBI
|
|
19
|
Islam F, Gopalan V, Vider J, Lu CT and Lam
AK: MiR-142-5p act as an oncogenic microRNA in colorectal cancer:
Clinicopathological and functional insights. Exp Mol Pathol.
104:98–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K,
Ren W, Zhang X, Shu P and Zhang D: miR-142-5p promotes development
of colorectal cancer through targeting SDHB and facilitating
generation of aerobic glycolysis. Biomed Pharmacother.
92:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Liu Z, Fang X and Yang H:
MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in
non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsang FH, Au SL, Wei L, Fan DN, Lee JM,
Wong CC, Ng IO and Wong CM: MicroRNA-142-3p and microRNA-142-5p are
downregulated in hepatocellular carcinoma and exhibit synergistic
effects on cell motility. Front Med. 9:331–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou K, Chen N, Li Z, Zhang B, Wang X, Chen
Y, Xu H, Wang D and Wang H: MicroRNA-142-5p overexpression inhibits
cell growth and induces apoptosis by regulating FOXO in
hepatocellular carcinoma cells. Oncol Res. 25:65–73. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Samuels Y and Waldman T: Oncogenic
mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol.
347:21–41. 2010.PubMed/NCBI
|
|
25
|
Vanhaesebroeck B, Stein RC and Waterfield
MD: The study of phosphoinositide 3-kinase function. Cancer Surv.
27:249–270. 1996.PubMed/NCBI
|
|
26
|
Zhang S, Cai J, Xie W, Luo H and Yang F:
miR-202 suppresses prostate cancer growth and metastasis by
targeting PIK3CA. Exp Ther Med. 16:1499–1504. 2018.PubMed/NCBI
|
|
27
|
Meng F and Zhang L: miR-183-5p functions
as a tumor suppressor in lung cancer through PIK3CA inhibition. Exp
Cell Res. 374:315–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu QQ, Wu H, Huang X, Shen H, Shu YQ,
Zhang B, Xiang CC, Yu SM, Guo RH and Chen L: MiR-1 targets PIK3CA
and inhibits tumorigenic properties of A549 cells. Biomed
Pharmacother. 68:155–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang M, Shi B, Liu J, He L, Yi G, Zhou L,
Yu G and Zhou X: Downregulation of miR203 induces overexpression of
PIK3CA and predicts poor prognosis of gastric cancer patients. Drug
Des Devel Ther. 9:3607–3616. 2015.PubMed/NCBI
|
|
30
|
Chen K, Zeng J, Tang K, Xiao H, Hu J,
Huang C, Yao W, Yu G, Xiao W, Guan W, et al: miR-490-5p suppresses
tumour growth in renal cell carcinoma through targeting PIK3CA.
Biol Cell. 108:41–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lv PC, Jiang AQ, Zhang WM and Zhu HL: FAK
inhibitors in Cancer, a patent review. Expert Opin Ther Pat.
28:139–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knapinska AM, Estrada CA and Fields GB:
The roles of matrix metalloproteinases in pancreatic cancer. Prog
Mol Biol Transl Sci. 148:339–354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu X, Gao F, Wang J, Tao L, Ye J, Ding L,
Ji W and Chen X: MiR-122-5p inhibits cell migration and invasion in
gastric cancer by down-regulating DUSP4. Cancer Biol Ther.
19:427–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zou Q, Yi W, Huang J, Fu F, Chen G and
Zhong D: MicroRNA-375 targets PAX6 and inhibits the viability,
migration and invasion of human breast cancer MCF-7 cells. Exp Ther
Med. 14:1198–1204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weber GL, Parat MO, Binder ZA, Gallia GL
and Riggins GJ: Abrogation of PIK3CA or PIK3R1 reduces
proliferation, migration, and invasion in glioblastoma multiforme
cells. Oncotarget. 2:833–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
